Navigation Links
Potential blood test for chronic sinusitis identified

A protein profile has been identified in the blood of chronic sinusitis sufferers that may enable physicians to objectively diagnosis and treat the disease, researchers say.

They used a sophisticated research tool that rapidly assesses expression of large numbers of proteins and found among 96 chronic sinusitis patients a profile missing in 38 healthy controls.

We can diagnose this disease with a totally objective test that does not depend on symptoms or observations, says Dr. Stilianos E. Kountakis, vice chair of the Department of Otolaryngology-Head and Neck Surgery in the Medical College of Georgia School of Medicine. He is corresponding author on the study published in the March/April issue of American Journal of Rhinology.

Diagnosing this chronically irritating disease, characterized by dripping noses, sinus pressure, congestion and difficulty breathing, currently is rather subjective. Patients talk about symptoms and doctors look at their sinuses with an endoscope and probably a computerized tomography scan. (O)verall management of (chronic sinusitis) is still hampered by the lack of quantifiable, molecular and genetic markers to aid in screening, researchers write.

To be classified chronic, the misery has to continue for at least 12 weeks. Causes include bacterial infections, respiratory inflammation, sinus polyps and mucosal disease. Some causes, such as polyps and asthma, have a genetic predisposition. You may have a bacterial infections, allergies, mechanical problems, Dr. Kountakis says. There are numerous genes that control respiratory function. Any of these things can go wrong to predispose the patient to develop chronic sinusitis.

Treating it isnt much more straightforward. Surgery can help correct anatomical causes such as deviated septums or polyps. However, there are no FDA-aproved drugs specifically to treat chronic sinusitis. Instead, physicians use drugs that treat symptoms: steroid sprays for inflammation, mucus thinners, saline irrigation, etc. Its difficult to show drugs are effective because its difficult to group patients together and measure their disease, says Dr. Kountakis.

He hopes further studies will enable both, revealing signature protein profiles for different types of chronic sinusitis as well as the degree of disease. The bottom line is we want to group patients according to their disease rather than just the general term chronic sinusitis, Dr. Kountakis says. If we can find a way to classify patients, group them together based on the specific disease they have, maybe we can get better outcomes and treat patients with better efficiency.

These objective measures should allow monitoring the effectiveness of current therapies and objectively reviewing new ones, he says.

In fact, even getting a handle on disease incidence is tough. The National Health Interview Survey, based on self-reports, says 14 to 16 percent of people in the United States have chronic sinusitis. A population-based study of the Olmsted County, Minnesota published in 2004 in Archives of Otolaryngology-Head & Neck Surgery put the incidence at 2 percent.

For this study, researchers analyzed protein expression in the blood using surface enhanced laser desorption ionization time-of-flight mass spectroscopy or SELDI-TOF-MS. The test is about 88 percent accurate.


Contact: Toni Baker
Medical College of Georgia

Related medicine news :

1. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
2. Stem cell research leads to potential new therapy for rare blood disorder
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Angina drug potentially useful against heart rhythm disorders
5. Neuronal regulators offer potential targets for cancer
6. Companies Not Fully Tapping Potential of Onsite Health Centers
7. Study Finds Potential Cause of Age-Related Macular Degeneration
8. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
9. New potential treatment for muscular dystrophy appears to be safe
10. Regenstrief Institute tapped by CDC to combat potentially catastrophic disease outbreaks
11. Research shows promise for potential new gene therapy strategy for muscle-wasting diseases
Post Your Comments:
Related Image:
Potential blood test for chronic sinusitis identified
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: